Serum S100B Levels in Patients with Liver Cirrhosis and Hepatic Encephalopathy

Hepatic encephalopathy (HE) is one of the main complications of liver cirrhosis (LC) and is classified into minimal hepatic encephalopathy (MHE) and overt hepatic encephalopathy (overt HE). S100B is expressed mainly in astrocytes and other glial cells, and S100B has been reported to be associated with various neurological disorders. The present study aimed to investigate the diagnostic ability of serum S100B to discriminate the grade of HE and the parameters correlated with serum S100B levels. Additionally, we investigated whether serum S100B levels can be used to predict 1-year mortality in cirrhotic patients. In total, 95 cirrhotic patients were consecutively enrolled and divided into the following three groups: (i) without any types of HEs; (ii) with MHE; and (iii) with overt HE. The diagnosis of MHE was made by the Mini-Mental State Examination (MMSE) and Psychometric Hepatic Encephalopathy Score (PHES). Among the three groups, there were no significant differences in serum S100B levels regardless of HE severity. The clinical parameters correlated with serum S100B levels were age, serum bilirubin, and creatinine levels. The Model for End-Stage Liver Disease (MELD) score showed a significant positive correlation with serum S100B levels. The relationship between serum S100B levels and MELD score was maintained in 48 patients without any type of HE. Additionally, hyperammonemia, low cholesterol levels, and the combination of serum S100B levels ≥ 35 pg/mL with MELD score ≥ 13 were factors for predicting 1- year mortality. In conclusion, serum S100B level was not useful for differentiating the severity of HE. However, we found that serum S100B levels can be affected by age, serum bilirubin, and creatinine in cirrhotic patients and are associated with MELD scores. Additionally, serum S100B levels showed the possibility of predicting 1-year mortality in cirrhotic patients. These findings suggest that serum S100B levels may reflect liver dysfunction and prognosis in liver disease.

[1]  R. Jalan,et al.  Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. , 2022, Journal of hepatology.

[2]  Y. Huang,et al.  Comprehensive analysis of the correlations of S100B with hypoxia response and immune infiltration in hepatocellular carcinoma , 2022, PeerJ.

[3]  A. Mancuso,et al.  Association of lipid profile with decompensation, liver dysfunction, and mortality in patients with liver cirrhosis , 2021, Postgraduate medicine.

[4]  N. Weiss,et al.  Diagnosis and Management of Hepatic Encephalopathy. , 2021, Clinics in liver disease.

[5]  Se Jin Park,et al.  Increased Expression of S100B and RAGE in a Mouse Model of Bile Duct Ligation-induced Liver Fibrosis , 2021, Journal of Korean medical science.

[6]  C. Piperi,et al.  Emerging role of S100B protein implication in Parkinson’s disease pathogenesis , 2020, Cellular and Molecular Life Sciences.

[7]  Shamsher Singh,et al.  Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders , 2020, Current neuropharmacology.

[8]  C. Leung,et al.  Interfering with S100B-effector protein interactions for cancer therapy. , 2020, Drug discovery today.

[9]  M. Shimizu,et al.  Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity score‐matching analysis , 2019, Journal of gastroenterology and hepatology.

[10]  Regina M. Hardison,et al.  Hepatic Encephalopathy in Children With Acute Liver Failure: Utility of Serum Neuromarkers. , 2019, Journal of pediatric gastroenterology and nutrition.

[11]  E. Vittinghoff,et al.  Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010–2014 National Inpatient Sample , 2019, Digestive Diseases and Sciences.

[12]  J. Undén,et al.  Clinical Use of the Calcium-Binding S100B Protein, a Biomarker for Head Injury. , 2019, Methods in molecular biology.

[13]  E. Tapper,et al.  Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. , 2015, Mayo Clinic proceedings.

[14]  K. Weissenborn.  Diagnosis of minimal hepatic encephalopathy. , 2015, Journal of clinical and experimental hepatology.

[15]  F. Poordad.  Presentation and complications associated with cirrhosis of the liver , 2015, Current medical research and opinion.

[16]  J. Talwalkar,et al.  Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. , 2014, Journal of hepatology.

[17]  M. Pavesi,et al.  Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). , 2014, Journal of hepatology.

[18]  P. Rudland,et al.  Joining S100 proteins and migration: for better or for worse, in sickness and in health , 2013, Cellular and Molecular Life Sciences.

[19]  P. Abreu-González,et al.  Summer/winter changes in serum S100B protein concentration as a source of research variance. , 2013, Journal of psychiatric research.

[20]  R. Donato,et al.  Functions of S100 proteins. , 2012, Current molecular medicine.

[21]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[22]  B. Romner,et al.  Clinical use of the calcium-binding S100B protein. , 2013, Methods in molecular biology.

[23]  J. West,et al.  All‐cause mortality in people with cirrhosis compared with the general population: a population‐based cohort study , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[24]  Carlos Guarner,et al.  Minimal Hepatic Encephalopathy Is Associated With Falls , 2011, The American Journal of Gastroenterology.

[25]  R. Gans,et al.  Body mass index and creatinine clearance are associated with steady-state serum concentrations of the cell damage marker S100B in renal transplant recipients. , 2010, Medical science monitor : international medical journal of experimental and clinical research.

[26]  R. Donato,et al.  S100B protein in myoblasts modulates myogenic differentiation via NF‐κB‐dependent inhibition of MyoD expression , 2010, Journal of cellular physiology.

[27]  C. Freitag,et al.  Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[28]  C. Heizmann,et al.  Binding of S100 proteins to RAGE: an update. , 2009, Biochimica et biophysica acta.

[29]  F. Brozzi,et al.  S100B's double life: intracellular regulator and extracellular signal. , 2009, Biochimica et biophysica acta.

[30]  A. Serdaroğlu,et al.  Tau and S100B proteins as biochemical markers of bilirubin-induced neurotoxicity in term neonates. , 2008, Pediatric neurology.

[31]  S. Terai,et al.  Serum S100b (astrocyte‐specific protein) is a useful marker of hepatic encephalopathy in patients with fulminant hepatitis , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[32]  F. Lecky,et al.  Rapid elimination of protein S-100B from serum after minor head trauma. , 2006, Journal of neurotrauma.

[33]  C. Heizmann,et al.  S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). , 2004, Biochemical and biophysical research communications.

[34]  P. Hayes,et al.  Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. , 2004, Journal of hepatology.

[35]  H. Redl,et al.  Release of S100B Differs During Ischemia and Reperfusion of the Liver, the Gut, and the Kidney in Rats , 2004, Shock.

[36]  William M. Lee,et al.  Serum protein S-100b in acute liver failure: Results of the US acute liver failure study group , 2003 .

[37]  Flávio Kapczinski,et al.  The serum S100B concentration is age dependent. , 2002, Clinical chemistry.

[38]  A. Lockwood,et al.  Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998 , 2002, Hepatology.

[39]  A. Eggermont,et al.  On the release and half‐life of S100B protein in the peripheral blood of melanoma patients , 2001, International journal of cancer.

[40]  G. Knudsen,et al.  S‐100b and neuron‐specific enolase in patients with fulminant hepatic failure , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[41]  C. Alling,et al.  Elimination of S100B and renal function after cardiac surgery. , 2000, Journal of cardiothoracic and vascular anesthesia.

[42]  David A. Case,et al.  The structure of calcyclin reveals a novel homodimeric fold for S100 Ca2+-binding proteins , 1995, Nature Structural Biology.

[43]  F. Michetti,et al.  Immunochemical detection of S-100 protein in non-nervous structures of the rabbit eye , 1985, Brain Research.

[44]  R. Wollmann,et al.  S-100 protein in human chondrocytes , 1982, Nature.

[45]  F. Michetti,et al.  Immunochemical and immunocytochemical localization of S-100 antigen in normal human skin , 1981, Nature.

[46]  B. Moore.  A soluble protein characteristic of the nervous system. , 1965, Biochemical and biophysical research communications.

[47]  S. Sherlock,et al.  Portal-systemic encephalopathy; neurological complications of liver disease. , 1954, Lancet.